working

Sign in

This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account

This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account


Sign In
Not a commercial user? Register here for our wider research bundle

More Content

More Content

Morning Note – 22 December 2025

Companies: Shield Therapeutics Plc (STX:LON)MHA Plc (MHA:LON)

Life Support - Cavendish Life Sciences quarterly sector note

Companies: GENI 4BB EDEN RUA AGY TSTL CNSL BVXP HVO KMK VLG IXI IHC STX CREO ANIC HCM POLB

Shield Therapeutics - ACCRUFeR US FDA approval for children >10 years

Companies: Shield Therapeutics Plc

Shield Therapeutics doubles Q2 revenue and sets sights on 2025 profitability with ACCRUFeR momentum

Companies: Shield Therapeutics Plc

PANMURE LIBERUM: FirstGroup: Sightseeing acquisition underpinned by property

Companies: FirstGroup plc

© Research Tree 2026

  • Apple Store
  • Play Store

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top